European Journal of Rheumatology
Invited Review

Pediatric antiphospholipid syndrome


Division of Pediatric Rheumatology, Department of Pediatrics, University of Michigan, Ann Arbor, Michigan, USA


Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA

Eur J Rheumatol 2020; 7: Supplement S3-S12
DOI: 10.5152/eurjrheum.2019.19160
Read: 3536 Downloads: 1638 Published: 31 January 2020

Despite its potential to cause significant morbidity in children, pediatric antiphospholipid syndrome (APS) is an understudied condition.  In this review, we will cover what is known about pediatric APS epidemiology and how the clinician might approach the diagnosis of pediatric APS.  We will highlight similarities and differences with the adult disease, both for primary APS and in the context of lupus.  Clinical manifestations beyond thrombosis, especially neurologic and hematologic in nature, will be discussed.  We will also consider what unique implications antiphospholipid antibody-positivity may have for children with lupus and for neonates born to mothers with APS.  The approach to treatment will be covered, including the unique impact of APS medications on children as compared with adults.  Finally, the importance of future mechanistic research is emphasized as physicians endeavor to provide the personalized care that children with APS clearly deserve.

Cite this article as: Madison JA, Zuo Y, Knight JS. Pediatric antiphospholipid syndrome. Eur J Rheumatol 2020; 7(Suppl 1): S3-S12

EISSN 2148-4279